Teva suffers setback on in-house asthma program as a PhII study is halted early due to futility

According to a Monday update posted on clinicaltrials.gov, Teva terminated a Phase II asthma study early due to futility following an interim analysis. The trial had been looking to evaluate the program known as TEV-48574 in 65 adults over 16 weeks, regardless if their severe asthma is triggered by allergens.